# Core 2: Glioblastoma Biorepository Core

> **NIH NIH P01** · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $172,590

## Abstract

PROJECT SUMMARY – CORE 2
Oncolytic herpes simplex virus (oHSV) based therapeutics represent a promising and novel treatment
approach for glioblastoma (GBM), which still has no effective conventional or targeted therapeutics. However,
significant barriers exist to optimizing oHSV therapy and the research of the Core and Program are designed to
gain knowledge that will allow improved designed and effectiveness of these agents. To achieve this the
Glioblastoma Biorepository Core (Core 2) will provide investigators and all projects centralized access to
authenticated resources essential to the planned experimental studies. These include human and mouse
glioblastoma samples, associated clinical and genomic data, cell lines, and xenografts. The Core will also offer
professional neuropathology and immunopathology expertise useful in interpretation of experimental results
and their clinical relevance. These services will greatly aid the program's investigations of mechanisms of
resistance to oHSV therapy and discovery of new approaches to improve oHSV treatment as single agent or in
combination with other treatments (e.g. checkpoint inhibitors). The Biorepository Core will achieve these
goals through three specific aims that support all the Projects. Aim 1 is to generate and maintain a repository
of consented glioblastoma samples and data. This will include sample triage by Neuropathologists and
distribution from the clinical trial of rQNestin34.5 planned in Project 2 and utilized by Projects 2, 3 and 4
(tissue and blood). Aim 2 is to create and distribute glioblastoma patient derived cell lines (PDCL) and
xenografts (PDX). These will be created from the rQNestin34.5 trial patients as well as non-trial GBM patients.
The Core will also provide and authenticate mouse syngeneic glioma models (e.g. GL261-N4, CT2A, 4C8)
utilized by all Projects. Aim 3 is to provide expert neuropathology, immunopathology, and molecular analysis of
glioblastoma tissues and models. This includes genomic sequencing (e.g. EGFRvIII in Project 1, RNA
expression to characterize targets relevant to oHSV trafficking and effects (e.g. Nestin Project 2, activated
NOTCH Project 3), and multiplex co-localization studies of tissue samples for immune cell markers of
lymphocytic, NK-cell (Project 4), and macrophage populations (e.g. PD1, PDL1, CD8) in collaboration with the
DFCI Center for Immunooncology. In total the studies planned will facilitate centralized and efficient
administration of resources and specialized expertise required to achieve the ambitious goals of the Program
and advance the field of oHSV therapeutics for glioma and other cancers.

## Key facts

- **NIH application ID:** 10019370
- **Project number:** 5P01CA163205-08
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** KEITH LLOYD LIGON
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $172,590
- **Award type:** 5
- **Project period:** 2013-02-07 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10019370

## Citation

> US National Institutes of Health, RePORTER application 10019370, Core 2: Glioblastoma Biorepository Core (5P01CA163205-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10019370. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*